Skip to main content
. 2022 Mar 9;13:856386. doi: 10.3389/fphar.2022.856386

FIGURE 2.

FIGURE 2

Effect of CANA on cardiac function. (A) Evaluation of the ratio of peak E to peak A (E/A) by echocardiography; (B) Left ventricular ejection fraction (EF); (C) Concentration of BNP in the serum; (D) Left ventricular anterior wall end diastole (LVAWd); (E) Left ventricular internal diameter end diastole (LVIDd); (F) Left ventricular mass AW; (G) Heart-to-body weight ratio (HW/BW); (H) Left ventricular anterior wall end systole (LVAWs); (I) Left ventricular internal diameter end systole (LVIDs); (J) Left ventricular posterior wall end systole (LVPWs); (K) Left ventricular posterior wall end diastole (LVPWd); (L) Fractional shortening (FS); CANA, canagliflozin; NSD, normal-salt diet; HSD, high-salt diet. ** p < 0.01 vs. NSD. # p < 0.05, ## p < 0.01 vs. HSD.